Lead Product(s) : VTx-002
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : University Medical Center
Deal Size : Undisclosed
Deal Type : Collaboration
UMC Utrecht and VectorY collaborate to identify biomarkers of ALS in new study
Details : The collaboration aims to support VectorY’s lead program, VTx-002, which is being evaluated in the early-stage clinical trial studies for the treatment of ALS.
Product Name : VTx-002
Product Type : Antibody
Upfront Cash : Undisclosed
June 18, 2024
Lead Product(s) : VTx-002
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : University Medical Center
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : VTx-002
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : UMC Utrecht
Deal Size : Undisclosed
Deal Type : Collaboration
UMC Utrecht and VectorY Therapeutics collaborate in ALS Biomarker Study
Details : VTx-002, a vectorized antibody that selectively clears misfolded and aggregated TDP-43 from the cytoplasm of neuronal cells, is being developed for the treatment of Amyotrophic Lateral Sclerosis.
Product Name : VTx-002
Product Type : Antibody
Upfront Cash : Undisclosed
June 17, 2024
Lead Product(s) : VTx-002
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : UMC Utrecht
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : KYN-5356
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Forbion
Deal Size : $62.1 million
Deal Type : Series A Financing
Kynexis Launched to Advance Precision Therapeutics for Brain Diseases
Details : Through the proceeds, Kynexis will advance its lead therapeutic candidate, KYN-5356, a potential first-in-class KAT-II inhibitor for the treatment of cognitive impairment associated with schizophrenia (CIAS), toward clinical development.
Product Name : KYN-5356
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 11, 2023
Lead Product(s) : KYN-5356
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Forbion
Deal Size : $62.1 million
Deal Type : Series A Financing
Lead Product(s) : AMT‑240
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AMT-240 is a one-time-administered gene therapy using uniQure’s miQURE gene-silencing technology to silence the toxic APOE variant, in combination with overexpressing a protective APOE variant as treatment for autosomal dominant Alzheimer’s disease p...
Product Name : AMT‑240
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
November 10, 2022
Lead Product(s) : AMT‑240
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : European Union
Deal Size : $2.5 million
Deal Type : Funding
DZNE and Intravacc Awarded EU Funding to Develop Vaccine Against Genetic ALS Variant
Details : DZNE developed an experimental vaccine that instructs the immune system to produce antibodies against these harmful poly-GA molecules. In a mouse model, this reduces poly-GA aggregates and largely prevents motor deficits.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 07, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : European Union
Deal Size : $2.5 million
Deal Type : Funding
Lead Product(s) : VTx-002
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : VTx-002, reduce TDP-43 pathological aggregates for treating ALS, TAR-DNA binding protein-43 is necessary for correct processing and transport of multiple mRNA’s that are essential for neuronal survival.
Product Name : VTx-002
Product Type : Antibody
Upfront Cash : Inapplicable
May 18, 2022
Lead Product(s) : VTx-002
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AAV-VecTabs
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
VectorY Presents New Pre-clinical data at the European Network for the Cure of ALS (ENCALS)
Details : The new data demonstrate therapeutic potential and versatility of VectorY’s VecTab platform technology, enabling development of secreted or intracellular antibody fragments that are AAV-VecTabs delivered to neurons and/or astrocytes, in vitro and in vi...
Product Name : AAV-VecTabs
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
February 06, 2022
Lead Product(s) : AAV-VecTabs
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AMT-210
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AMT-210 (miRNA-based AAV Gene Therapy) is a one-time, brain-targeting AAV gene therapy incorporating miQURE gene silencing technology, designed to halt misfolded alpha-synuclein and subsequent fibril formation in familial and sporadic Parkinson’s disea...
Product Name : AMT-210
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 05, 2022
Lead Product(s) : AMT-210
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Forbion
Deal Size : $36.7 million
Deal Type : Financing
Details : Proceeds to establish pre-clinical proof of concept for vectorized antibodies in ALS and Alzheimer’s and to further expand the team.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
June 15, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Forbion
Deal Size : $36.7 million
Deal Type : Financing